Last checked at 
LONDON (Alliance News) - Scancell Holdings PLC said Friday it will undertake a Phase II clinical study for its lead cancer vaccine SCIB1 for patients with late stage melanoma, expected to start in the second half of 2016.
The trial is expected to run for around 18 months.
The company has formed its core US investigator team to undertake the study, which is intended to enrol around 80 stage 3/4 metastatic melanoma patients.
Shares in Scancell were up 0.3% at 13.66 pence Friday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
